A prospective observational study evaluating c-MET expression and EGFR gene mutation correlation with erlotinib response in second line treatment for advanced/metastatic non-small cell lung cancer patients

被引：0
|
作者：
Park, Cheol-Kyu
Choi, Yoo-Duk
Oh, In-Jae
Lee, Jung-Eun
Lee, Shin Yup
Jang, Tae-Won
Ryu, Jeong-Seon
Kim, Young-Chul
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2773
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer
    Park, Cheol-Kyu
    Oh, In-Jae
    Choi, Yoo-Duk
    Jang, Tae-Won
    Lee, Jeong-Eun
    Ryu, Jeong-Seon
    Lee, Shin-Yup
    Kim, Young-Chul
    ONCOLOGY, 2018, 94 (06) : 373 - 382
  • [2] A PROSPECTIVE OBSERVATIONAL STUDY EVALUATING C-MET EXPRESSION AND EGFR GENE MUTATION CORRELATION WITH ERLOTINIB RESPONSE IN 2ND LINE TREATMENT FOR ADVANCED/METASTATIC NSCLC PATIENTS - INTERIM ANALYSIS
    Oh, I-J
    Choi, Y-D
    Song, S-Y
    Choi, S.
    Shin, H-J
    Park, C-K
    Lee, B-R
    Ban, H-J
    Kwon, Y-S
    Kim, K-S
    Kim, Y-Il
    Lim, S-C
    Kim, Y-C
    Yoon, S-H
    RESPIROLOGY, 2014, 19 : 159 - 159
  • [3] EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer
    Weber, Britta
    Hager, Henrik
    Sorensen, Boe S.
    McCulloch, Tine
    Mellemgaard, Anders
    Khalil, Azza Ahmed
    Nexo, Ebba
    Meldgaard, Peter
    LUNG CANCER, 2014, 83 (02) : 224 - 230
  • [4] Mechanism of EGFR and c-Met TKI resistance and role of co-expression of EGFR and c-Met in non-small cell lung cancer patients
    Botting, Gregory Michael
    Harrington, Kymberly
    Shearrow, Caleb
    Crees, Zachary
    Girard, Jennifer
    Arasi, Kavin
    Puri, Neelu
    CANCER RESEARCH, 2014, 74 (19)
  • [5] C-MET inhibitors for advanced non-small cell lung cancer
    Pasquini, Giulia
    Giaccone, Giuseppe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 363 - 375
  • [6] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [7] Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer
    Fu, Le
    Guo, Wei
    Liu, Bingshan
    Sun, Linlin
    Bi, Zhenghong
    Zhu, Li
    Wang, Xinyan
    Liu, Bin
    Xie, Qian
    Li, Ke
    BIOMARKERS, 2013, 18 (02) : 126 - 135
  • [8] Analysis of c-Met gene amplification in Japanese patients with advanced non-small cell lung cancer (NSCLC)
    Sone, T.
    Kasahara, K.
    Sakai, A.
    Ikeda, H.
    Kurokawa, K.
    Fujimura, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] ANALYSIS OF C-MET GENE AMPLIFICATION IN JAPANESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Sone, Takashi
    Matsui, Tomohiro
    Kurokawa, Kouji
    Sakai, Asao
    Kasahara, Kazuo
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S462 - S462
  • [10] ERLOTINIB in Second Line Treatment of Metastatic Lung Cancer: About 20 Case of Non-Small Cell LUNG
    Teyar, Nahla
    Bensaou, Malika Gamaz
    Bouzid, Kamel
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1498 - S1499
12345